SCHEMBL7426634

SCHEMBL7426634

CC(=O)OC(=Cc1ccccc1)c1ccc(OC(C)=O)c(OC(C)=O)c1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.41
MEN1 O00255 7/20 0.41
KMT2A Q03164 7/20 0.41
LMNA P02545 4/20 0.41
NPC1 O15118 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HTT P42858 3/20 0.41
RAB9A P51151 3/20 0.41
GAA P10253 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HSP90AA1 P07900 1/20 0.40
CCR6 P51684 1/20 0.40
MAPK1 P28482 2/20 0.39
FBP1 P09467 1/20 0.39
RECQL P46063 2/20 0.38
HPGD P15428 2/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7426625 1.00 MAPT (0.41) MAPTMEN1KMT2ALMNANPC1
SCHEMBL27575919 0.81 HSP90AA1 (0.56) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7513057 0.75 PTPN1 (0.43) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7513063 0.72 MAPK1 (0.43) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7432671 0.72 NPC1 (0.41) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7282880 0.70 SMN1; SMN2 (0.44) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7520323 0.69 HSP90AA1 (0.44) MAPTMEN1KMT2ALMNANPC1
SCHEMBL11761126 0.67 MAPK1 (0.65) MAPTMEN1KMT2ALMNANPC1
SCHEMBL10006253 0.67 AKR1C3 (0.50) MAPTMEN1KMT2ALMNANPC1
SCHEMBL4982106 0.67 AKR1C3 (0.50) MAPTMEN1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1454203-A Substituted nitrated catechols, their use in the treatment of certain central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & CA SA (PT) 2003-11-05 CN claimed
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US claimed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP claimed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO claimed
CN-1454203-A Substituted nitrated catechols, their use in the treatment of certain central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & CA SA (PT) 2003-11-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 MAPT 379/4885MEN1 1966/4885KMT2A 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.